Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Jingwen Wang, Bo Jia et al.|Journal of Hematology & Oncology|2017Cited by 256
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Jun Zhu, Meifang Zheng et al.|The Lancet Oncology|2023Cited by 55
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphomaYuankai Shi, Xin Zhang, Yongping Song et al.|Journal of Hematology & Oncology|2020Cited by 50
ADAR1-mediated RNA editing promotes B cell lymphomagenesisRiccardo Pecori, Qiang Pan‐Hammarström, Weicheng Ren et al.|iScience|2023Cited by 24
Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patientsYue Fei, Huilai Zhang|Journal of Cancer|2020Cited by 22